On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8–6 with one abstention to recommend adding BPC-157 to the 503A compounding list — overruling the FDA’s own briefing document, which had proposed against it. But the vote is non-binding and changes nothing today: BPC-157 remains a Category 2 substance and is still not legally available through patient-specific compounding. It has never been FDA-approved as a drug and is not a dietary supplement.
What actually happened on July 23, 2026
BPC-157 and KPV were the first two peptides taken up at the Pharmacy Compounding Advisory Committee (PCAC) meeting, and the committee voted to recommend both for the 503A Bulks List. On BPC-157 the tally was eight in favor, six against, one abstention.
The notable part is that the committee went against the FDA’s own staff position. The agency’s briefing documents had proposed that none of the seven peptides under review — BPC-157, KPV, TB-500, MOTs-C, and, on July 24, Emideltide (DSIP), Semax, and Epitalon — be added to the list, citing insufficient effectiveness and safety evidence and incomplete physical and chemical characterization.
The reasoning from members voting yes was largely harm-reduction: that patients are already obtaining these peptides from the unregulated gray market, and supervised compounding is the safer of two imperfect options. Reporting on the meeting also noted that many of the yes votes came from committee members who represent or advise telehealth companies — an industry with a direct commercial interest in peptide access. Both facts belong in an honest reading of the result.
Why this does not make BPC-157 legal
Three things have to be true before a licensed pharmacy could legally compound BPC-157 for you, and only the first has happened:
- The advisory committee recommends it — done, as of July 23, 2026, but the recommendation is non-binding.
- The FDA decides to follow it. The agency makes the final determination and is not obliged to accept the committee’s view; here it would mean reversing its own published position.
- Formal rulemaking completes. Adding a substance to the 503A list runs through notice-and-comment rulemaking, historically a process of more than a year.
Until all three land, the current restriction stands. Anyone selling BPC-157 for human use today, or citing the July vote as proof that it is now legal, is ahead of the rule.
What “Category 2” still means
The FDA sorts bulk substances that compounding pharmacies want to use into interim categories. Category 1 substances may be compounded by 503A pharmacies under a valid prescription while under review. Category 2 substances — where BPC-157 sits today — have been flagged with potential safety, quality, or characterization questions and may not be compounded during that review.
Worth separating clearly: a place on the compounding list is not FDA approval. It would permit licensed pharmacies to prepare the substance under prescription. It would not mean BPC-157 has passed clinical trials, nor establish proven safety, efficacy, or standardized dosing.
Why the “research chemical” route is a problem
Because there is no legal compounding pathway, BPC-157 sold online is typically labeled “for research use only, not for human consumption.” That labeling is a legal disclaimer, not a safety feature: these products are not prepared under pharmacy quality standards, and independent testing of the gray market has repeatedly found mislabeling and contamination concerns across peptide products. There is no clinical oversight, no verified dose, and no recourse. Our guide to compounded peptides vs research chemicals covers the difference in detail.
If you are interested in peptides legally
Start with the peptides that have a real legal pathway today — FDA-approved tesamorelin, and Category 1 sermorelin and ipamorelin — under a licensed clinician who can match a peptide to your goals and labs. See what peptides are legal in 2026 for the full status map.
BPC-157 is not FDA-approved and, as of July 23, 2026, is not eligible for legal patient-specific compounding. The advisory committee’s recommendation is non-binding and does not change current status. Nothing here is medical advice or a promise of results. This area is moving quickly — verify current FDA listings before acting.
Frequently asked questions
Is BPC-157 legal to buy in 2026? Not yet. The July 23 committee vote was a non-binding recommendation; BPC-157 remains Category 2 until the FDA acts and rulemaking completes.
Did the FDA approve BPC-157? No. The committee recommended it for the compounding list — a different question from drug approval, which BPC-157 has never had.
Why did the committee vote yes when FDA staff said no? Members largely cited harm reduction versus the gray market. Reporting noted many yes votes came from members tied to telehealth companies with a commercial interest.
When could it actually become legal? Only after the FDA accepts the recommendation and completes notice-and-comment rulemaking — historically over a year.
What legal peptides are similar? Sermorelin, ipamorelin, and tesamorelin have legal pathways but different mechanisms; discuss with a clinician.
Sources
- FDA, “July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee,” agenda + briefing documents (fda.gov), captured 2026-07-23.
- Contemporaneous reporting on the July 23, 2026 PCAC session, including the 8–6–1 BPC-157 vote, the KPV vote, and committee-member affiliations (STAT), captured 2026-07-23.
- FDA Law Blog, “FDA’s Pep(tide) Rally,” 2026-04 (thefdalawblog.com), on PCAC process and rulemaking timelines.
Status as of 2026-07-23. This page is on a 30-day re-verification cycle while FDA action is pending.